Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ospemifene Hormos.

Luigi Gennari1

  • 1Department of Internal Medicine, Endocrine-Metabolic Sciences and Biochemistry, University of Siena, Policlinico Le Scott, 53100-Siena, Italy. gennari@unisi.it

Current Opinion in Investigational Drugs (London, England : 2000)
|May 12, 2004
PubMed
Summary

Hormos Medical is investigating ospemifene, a selective estrogen receptor modulator, for treating postmenopausal osteoporosis and urogenital atrophy. Clinical trials were in phase II/III by November 2003.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Osteoporosis associated with pregnancy and lactation (PLO): can REMS have a role in prevention and follow-up?

Endocrinology, diabetes & metabolism case reports·2026
Same author

Across Clinical Profiles of Cardiorenal-Metabolic (CKM) Syndrome: A Phenotype-Driven Therapeutic Approach.

Biomedicines·2026
Same author

Endocrine-related osteoporosis: the state of the art.

Frontiers in endocrinology·2026
Same author

Burosumab an emerging therapy in TIO: a local clinical survey and a systematic review with individual patient data analysis.

Frontiers in endocrinology·2026
Same author

Association of Sport Participation and Calcium Intake with Bone Mineral Density in Children and Adolescents: A Cross-Sectional Study.

Children (Basel, Switzerland)·2026
Same author

Correction: Vitamin D intake in Italian healthy subjects and patients with different pathological disorders.

Frontiers in nutrition·2026

Area of Science:

  • Pharmacology
  • Endocrinology
  • Women's Health

Background:

  • Selective estrogen receptor modulators (SERMs) offer therapeutic potential for hormone-related conditions.
  • Postmenopausal osteoporosis and urogenital atrophy are significant health concerns affecting women.
  • Ospemifene is a SERM being developed by Hormos Medical.

Purpose of the Study:

  • To evaluate the efficacy and safety of ospemifene for treating postmenopausal osteoporosis.
  • To assess ospemifene's potential in managing urogenital atrophy in postmenopausal women.

Main Methods:

  • Clinical development of ospemifene.
  • Phase II/III clinical trials were initiated for both osteoporosis and urogenital atrophy indications.
  • Data collection and analysis from ongoing trials.

Main Results:

  • Ospemifene demonstrated potential in preclinical and early clinical studies (data not detailed in abstract).
  • Advancement to phase II/III testing indicates promising preliminary findings.
  • Further results are pending from ongoing clinical trials.

Conclusions:

  • Ospemifene shows promise as a novel therapeutic agent for postmenopausal conditions.
  • Continued clinical evaluation is necessary to confirm its efficacy and safety profile.
  • Ospemifene may offer a new treatment option for osteoporosis and urogenital atrophy.

Related Experiment Videos